Search results
Results From The WOW.Com Content Network
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein.
You know a company isn't in a good place when investors enthusiastically greet an event that could cause its demise. That's exactly what happened to Dendreon (NAS: DNDN) on Friday. The biotech has ...
Dendreon (NAS: DNDN) has thrown in the towel. Given up. Waved the white flag. Admitted defeat. And investors aren't too happy about it. The company is closing the New Jersey plant that ...
The fall of Dendreon is a grim cautionary tale for biotech investors. The stock has fallen more than 40% year to date, and is down more than 90% since its peak in 2010. Wall Street had believed ...
What: Shares of cancer-drug developer Dendreon (NAS: DNDN) were getting slammed today, losing 23% as investors reacted to the company's continued struggles to grow sales of its key prostate-cancer ...
Dendreon (NAS: DNDN) closed below $10 per share yesterday for the first time since 2009. More shockingly, if you bought the IPO back in 2000, you're now sitting on a slight loss some 11 years and ...
What: Shares of Dendreon -- developer of the Food. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they ...
Since Dendreon reported its second-quarter earnings, the stock has declined 40%. Following the quarter, analysts from Wedbush and Deutsche Bank issued price targets of $0 and $1, respectively ...